Strategic Asset Sale Theralink recently divested assets to IMAC Holdings Inc., indicating a potential shift in go-to-market strategy or partnership opportunities with buyers in the precision medicine space. This could open avenues for co-development, licensing, or continued service relationships around their phosphoprotein-based assays.

Clinical Adoption Focus Their phosphoproteomic RPPA platform uniquely quantifies drug target activation states within tumor tissue, offering a decision-support tool that could appeal to oncologists and biopharma sponsors pursuing biomarker-driven trials and companion diagnostics.

Pan-tumor Expansion Theralink has expressed development plans for a second, pan-tumor assay targeting multiple solid tumors, creating cross-market opportunities across oncology indications and expanding the potential customer base beyond breast cancer.

Commercial Leadership Recent leadership appointments and a focus on commercialization suggest investment in market access, sales execution, and customer education—areas ripe for collaboration with CROs, payers, and biopharma partners to accelerate adoption.

Strategic Partnerships Past collaborations (for example with Perthera) signal openness to strategic alliances in precision oncology, offering potential for co-development, data-sharing arrangements, or service integrations with firms pursuing advanced molecular profiling.